This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
6 - 8 June, 2023
Postillon Hotel AmsterdamDigital Experience: All Sessions Live-streamed 6-8 June, 2023

Audrey Desgranges
CEO at McSAF Inside® Oncology


As an engineer specializing in organic chemistry and formulation, Audrey has evolved in a mixed environment combining R&D and the valorisation of patented technologies within academic teams and industry (Boehringer Ingelheim). In late 2017, Audrey joined McSAF and is in charge of operations.

In 2018, she initiates a collaboration between McSAF and academic teams of researchers and clinicians to evaluate the relevance of ADC strategy in Merkel Cell Carcinoma using McSAF bioconjugation tools via CD56 targeting. Then, she identified and planed project phases from discovery to clinical via identifying and interacting with external experts for ADCITMER® evaluation. She will convert her position as CEO to lead the development of ADCITMER® joining McSAF Inside Oncology the dedicated affiliate of McSAF.

Agenda Sessions

  • ADCITMER® A Promising Anti CD56 Antibody-drug Conjugate to Treat Metastatic Merkel Cell Carcinoma